Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab

Elie El Rassy, Tarek Assi, Jamale Rizkallah, Joseph Kattan

Résultats de recherche: Contribution à un journalArticleRevue par des pairs

18 Citations (Scopus)

Résumé

Immune checkpoint inhibitors (ICIs) are actually being indicated more commonly in the management of chemoresistant cancer patients in view of their favorable toxicity profile in comparison to cytotoxic chemotherapy. In this paper, we report, to our knowledge, the first case suggestive of cytokine release syndrome secondary to pembrolizumab in a patient with metastatic lung squamous cell carcinoma. In view of the quick approvals of ICI and the absence of sufficient knowledge of the corresponding toxicity profile, the occurrence of any clinical or biological sign or symptom in patients receiving ICI requires further investigation.

langue originaleAnglais
Pages (de - à)309-311
Nombre de pages3
journalImmunotherapy
Volume9
Numéro de publication4
Les DOIs
étatPublié - 1 mars 2017
Modification externeOui

Contient cette citation